|Bid||29.2200 x 200|
|Ask||29.2500 x 200|
|Day's Range||29.0800 - 29.5200|
|52 Week Range||24.8100 - 33.9600|
|PE Ratio (TTM)||-116.06|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On May 16, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).
Genomic Health, Inc. (GHDX), a global cancer company, recently presented positive results for its Oncotype DX Genomic Prostate Score (GPS) test.
Meanwhile, the genetic-test maker is increasing margins on its way to profitability.